SURVYR

ZLAB

Zai Lab Limited
$24.06
+$0.87 (3.75%)Oct 19 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-44%-29%-14%+2%+17%Oct 2025Oct 2026Apr 202652w high $27.5052w low $15.96
ZLABSPY
Wall St. Highest PT $50.00 (+107.8%) Wall St. Avg PT $33.14 (+37.7%)
$16$25$34$43$52POC $19Hi $50Avg $33
Underwater Drawdown %Max DD -44.1%Current -17.5%
0.0%-44.1%
Relative Strength vs SPY-31.7% vs SPYUnderperforming
+62%0%-62%
1W
−$0.53 (2.16%)
1M
−$1.64 (6.38%)
3M
+$3.54 (17.25%)
6M
−$1.19 (4.71%)
YTD
+$6.42 (36.39%)
1Y
−$4.23 (14.95%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
12 analysts · mean score 1.33
1 = Strong Buy · 5 = Sell
Strong Buy975%
Buy217%
Hold18%
Underperform00%
Sell00%
Wall Street consensus · as of Sep 28, 2026
Analyst price targets
Current price$24.06
Average target$33.14
+$9.08 (+37.7%) upsideaverage target vs current price
CurrentAverageMedian
Low$24.25
Median$31.84
High$50.00
12-month Wall Street target range · as of Sep 23, 2026
Recent analyst rating changes · 30
Reiterated
2026-08-07 · Citigroup reiterated Buy on ZLAB
Reiterated
2026-05-08 · Citigroup reiterated Buy on ZLAB
Reiterated
2026-03-18 · JP Morgan reiterated Overweight on ZLAB
Reiterated
2026-02-27 · Cantor Fitzgerald reiterated Overweight on ZLAB
Reiterated
2026-02-05 · JP Morgan reiterated Overweight on ZLAB
Initiated
2026-01-07 · UBS started covering ZLAB at Buy
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$2.7B
P/E (next 12 months, estimated)-11.4
52-week range$15.96 – $27.50
Revenue growth (latest quarter vs a year ago)-3.3%
Dividend yieldNo dividend
Analyst consensusStrong Buy (12)
Average analyst price target$33.14 (+38%)

What they do

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd..

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for ZLAB yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

ZLAB earningsNext report in 8 days
Next report · quarter Sep 2026
Thu Nov 5, 2026Before the open
EPS consensus-$0.56 range -$0.67–-$0.49
Revenue consensus$108.8M 6 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$0.46est -$0.68+32.3%Above estimates
May 7, 2026-$0.46est -$0.53+12.6%Above estimates
Feb 26, 2026-$0.46est -$0.42−8.4%Below estimates
Nov 6, 2025-$0.33est -$0.29−12.9%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-25 23:35:47 ET
24-1125-0225-0525-0825-1126-0226-0526-08-0.800.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$106.3M-3.3%
2026-03-31$99.6M–
2025-12-31$127.6M–
2025-09-30$116.1M–
2025-06-30$110.0M–

News & catalysts

More news
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
MT Newswires · Oct 23
Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study
MarketBeat · Oct 23
Sector Update: Healthcare Stocks Fall Premarket Friday
MT Newswires · Oct 23
Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
PR Newswire · Oct 23
Zai Lab Says Zoci Plus Atezolizumab Improves Response Rate in Phase 1 Lung Cancer Trial
MT Newswires · Oct 23
Rating changes
Reiterated
2026-08-07 · Citigroup reiterated Buy on ZLAB
Reiterated
2026-05-08 · Citigroup reiterated Buy on ZLAB
Reiterated
2026-03-18 · JP Morgan reiterated Overweight on ZLAB
Reiterated
2026-02-27 · Cantor Fitzgerald reiterated Overweight on ZLAB
Reiterated
2026-02-05 · JP Morgan reiterated Overweight on ZLAB
Initiated
2026-01-07 · UBS started covering ZLAB at Buy

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-25 23:35:47 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026